The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1566
February 25, 2019
View Complete Issue         Table of Contents 2019 
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
February 25, 2019 (Issue: 1566)
The FDA has required manufacturers of the oral P2Y12 platelet inhibitors clopidogrel (Plavix, and generics), prasugrel (Effient, and generics), and ticagrelor (Brilinta) to warn in the product labels that the absorption of these drugs may be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
Article code: 1566e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.